Concepedia

Author

Pedro Oyuela

University of Cambridge

Also Known As

P. Oyuela, Pedro Oyuela

22

Publications

1.6K

Citations

8

H-Index

10

Concepts

All Affiliations

University of CambridgeAssociates in NeurologyCleveland ClinicMcGill UniversityBrigham and Women's Hospital
PO

About

Pedro Oyuela is an author at University of Cambridge specializing in multiple sclerosis, medicine, and nephrology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

1.2K

2

Immunology

1

1

1.2K

3

Nephrology

1

1

39

4

Pathology

1

1

39

5

Autoimmune Disease

1

1

39

Pedro Oyuela

×

7

Publications

1.5K

Citations

7

H-Index

YearCitations

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Alasdair Coles, Cary Twyman, Douglas L. Arnold,

The Lancet

2012

1.2K

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis

Gilbert H. Daniels, Anton Vladić, Vesna Brinar,

The Journal of Clinical Endocrinology & Metabolism

2013

146

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

Adam Cuker, Alasdair Coles, H. R. Sullivan,

Blood

2011

105

Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) Program

Christina Caon, Marie Namey, Cathy Meyer,

International Journal of MS Care

2015

47

Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing–remitting multiple sclerosis

David Meyer, Alasdair Coles, Pedro Oyuela,

Multiple Sclerosis and Related Disorders

2012

39

Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001)

Edward Fox, Douglas L. Arnold, Jeffrey Cohen,

Neurology

2013

13

Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the CARE-MS Studies (P2.199)

Cary Twyman, Pedro Oyuela, Jeffrey Palmer,

Neurology

2014

13

Page 1